Diabetes Mellitus, Non-Insulin-Dependent
Item
patients with type 2 diabetes
boolean
C0011860 (UMLS CUI [1])
Metformin
Item
metformin monotherapy > 12 weeks
boolean
C0025598 (UMLS CUI [1])
Hemoglobin A1c measurement
Item
hemoglobin a1c (hba1c) > 6.5 % and < 9.0 %
boolean
C0474680 (UMLS CUI [1])
Body mass index
Item
body mass index (bmi) 19-35 (kg/m²)
boolean
C1305855 (UMLS CUI [1])
Acute Disease
Item
acute diseases at randomization
boolean
C0001314 (UMLS CUI [1])
Kidney Diseases | Creatinine measurement, serum | Glomerular Filtration Rate
Item
kidney diseases with creatinin > 120 µmol/l, glomerular filtration rate (gfr) <50 ml/min
boolean
C0022658 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
C0017654 (UMLS CUI [3])
Medical contraindication Gliptins | Medical contraindication Glucagon-Like Peptide Analogue
Item
contraindication for gliptins or glucagon-like-peptide-analogues according to the respective summary of product characteristics (smpc)
boolean
C1301624 (UMLS CUI [1,1])
C1827106 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0014361 (UMLS CUI [2,2])
C0243071 (UMLS CUI [2,3])
Dipeptidyl-Peptidase IV Inhibitors | GLP-1 Mimetics
Item
previous use of dipeptidyl peptidase-4-inhibitors and glp-1-mimetics
boolean
C1827106 (UMLS CUI [1])
C3273809 (UMLS CUI [2])
Eligibility Criteria Study Protocol
Item
other protocol-defined inclusion/exclusion criteria may apply.
boolean
C1516637 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])